Search research articles
Contact Us
Filters
Showing results (81-90 of 87) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 87 results.
Journal of Biomolecular Screening
|
January 1, 2015
Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies
Peter S Kutchukian, Anne Mai Wassermann, Mika K Lindvall, et al.
Clinical Cardiology
|
April 13, 1999
NC100100, a new echo contrast agent for the assessment of myocardial perfusion--safety and comparison with technetium-99m sestamibi single-photon emission computed tomography in a randomized multicenter study
T Binder, P Assayag, F Baer, et al.
Journal of the American College of Cardiology
|
November 11, 1998
Accuracy and feasibility of contrast echocardiography for detection of perfusion defects in routine practice: comparison with wall motion and technetium-99m sestamibi single-photon emission computed tomography. The Nycomed NC100100 Investigators
T H Marwick, R Brunken, N Meland, et al.
Molecular Cancer Research : MCR
|
February 21, 2014
Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers
Ida Aronchik, Brent A Appleton, Stephen E Basham, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor
Alexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria
Robert J Moreau, Colin K Skepper, Brent A Appleton, et al.
Journal of Medicinal Chemistry
|
October 28, 2015
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies
Matthew T Burger, Gisele Nishiguchi, Wooseok Han, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 87) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 87 results.
Journal of Biomolecular Screening
|
January 1, 2015
Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies
Peter S Kutchukian, Anne Mai Wassermann, Mika K Lindvall, et al.
Clinical Cardiology
|
April 13, 1999
NC100100, a new echo contrast agent for the assessment of myocardial perfusion--safety and comparison with technetium-99m sestamibi single-photon emission computed tomography in a randomized multicenter study
T Binder, P Assayag, F Baer, et al.
Journal of the American College of Cardiology
|
November 11, 1998
Accuracy and feasibility of contrast echocardiography for detection of perfusion defects in routine practice: comparison with wall motion and technetium-99m sestamibi single-photon emission computed tomography. The Nycomed NC100100 Investigators
T H Marwick, R Brunken, N Meland, et al.
Molecular Cancer Research : MCR
|
February 21, 2014
Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers
Ida Aronchik, Brent A Appleton, Stephen E Basham, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor
Alexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria
Robert J Moreau, Colin K Skepper, Brent A Appleton, et al.
Journal of Medicinal Chemistry
|
October 28, 2015
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies
Matthew T Burger, Gisele Nishiguchi, Wooseok Han, et al.
Page
of 9